FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091462862> ?p ?o ?g. }

• W2091462862 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CADespite the identification of several preventive agents and strategies, prevention of lung cancer, especially in smokers who are at high risk, is still largely unattained. 1,4-Phenylenebis(methylene)selenocyanate (p-XSC) has been shown to inhibit tobacco carcinogen NNK induced lung cancer development in several animal models. It metabolizes through the formation of active bis-selenol (p-XSeH) along with the release of poisonous hydrogen cyanide (HCN). Nevertheless, the HCN released upon metabolism of p-XSC to form active metabolite p-XSeH, pose a serious challenge its clinical use in a chemopreventive set up where a continuous intake is required for healthy individuals over a longer period of time. Recently, we developed a hybrid agent, p-XS-Asp, linking p-XSe- to commonly used non-steroidal anti-inflammatory drug, aspirin (Asp), which has been shown to be preventive of lung, and colorectal cancer. We hypothesized that p-XS-Asp would cleave in vivo to release the active p-XSeH, not releasing undesired HCN but the aspirin, thus making the compound less toxic and more potent than p-XSC or aspirin alone. Our studies have shown p-XS-Asp to be orally bioavailable and a highly effective lung cancer chemopreventive agent both in vitro and in animal studies. Elemental selenium (Se) analysis of plasma, lung, and liver tissue in orally fed mice showed that the level of Se significantly higher for p-XS-Asp than p-XSC, denoting a better bioavailability profile for p-XS-Asp. Dietary p-XS-Asp inhibited both O-6 methyl guanine and pyridoxobutyl (pob) DNA adducts, in lung and liver of A/J mice, more effectively than p-XSC. Particularly, in the lung, the inhibition of O-6 methyl guanine adducts, which are critical for A/J mouse lung tumor development, were more than 2 times higher than p-XSC. In a NNK-induced lung cancer A/J mouse model, p-XS-Asp at doses of 15 ppm and 7.5 ppm Se, showed a significantly marked decrease in percentage of lung tumor incidence of 50% and 87%, as compared to p-XSC (79% and 100%), respectively; NNK-control showed an 100% tumor incidence. In addition, the multiplicity for p-XS-Asp was 0.87 and 1.93 tumors/mouse as compared with NNK-control (11.53 tumors/mouse) and p-XSC (1.66 and 4.10 tumors/mouse, respectively) at the two doses tested. Notably, blood and tissue analyses showed no signs of systemic toxicity for the p-XS-Asp fed group. In conclusion, p-XS-Asp, is less toxic and more effective chemopreventive agent than p-XSC and is a promising candidate to future clinical evaluation.Citation Format: Daniel Plano, Cesar Aliaga, Manoj K. Pandey, Arunangshu Das, Timothy K. Cooper, Shantu Amin, Arun K. Sharma. Pre-clinical chemopreventive efficacy of a novel hybrid p -XSC-aspirin compound in a NNK-induced A/J mouse lung cancer model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2139. doi:10.1158/1538-7445.AM2014-2139" @default.
• W2091462862 created "2016-06-24" @default.
• W2091462862 creator A5018954418 @default.
• W2091462862 creator A5027849001 @default.
• W2091462862 creator A5041438744 @default.
• W2091462862 creator A5048058203 @default.
• W2091462862 creator A5063979460 @default.
• W2091462862 creator A5071573524 @default.
• W2091462862 creator A5074970912 @default.
• W2091462862 date "2014-09-30" @default.
• W2091462862 modified "2023-09-27" @default.
• W2091462862 title "Abstract 2139: Pre-clinical chemopreventive efficacy of a novel hybridp-XSC-aspirin compound in a NNK-induced A/J mouse lung cancer model" @default.
• W2091462862 doi "https://doi.org/10.1158/1538-7445.am2014-2139" @default.
• W2091462862 hasPublicationYear "2014" @default.
• W2091462862 type Work @default.
• W2091462862 sameAs 2091462862 @default.
• W2091462862 citedByCount "0" @default.
• W2091462862 crossrefType "proceedings-article" @default.
• W2091462862 hasAuthorship W2091462862A5018954418 @default.
• W2091462862 hasAuthorship W2091462862A5027849001 @default.
• W2091462862 hasAuthorship W2091462862A5041438744 @default.
• W2091462862 hasAuthorship W2091462862A5048058203 @default.
• W2091462862 hasAuthorship W2091462862A5063979460 @default.
• W2091462862 hasAuthorship W2091462862A5071573524 @default.
• W2091462862 hasAuthorship W2091462862A5074970912 @default.
• W2091462862 hasConcept C112705442 @default.
• W2091462862 hasConcept C114246631 @default.
• W2091462862 hasConcept C121608353 @default.
• W2091462862 hasConcept C126322002 @default.
• W2091462862 hasConcept C149151106 @default.
• W2091462862 hasConcept C150903083 @default.
• W2091462862 hasConcept C181389837 @default.
• W2091462862 hasConcept C185592680 @default.
• W2091462862 hasConcept C207001950 @default.
• W2091462862 hasConcept C2776256026 @default.
• W2091462862 hasConcept C2777477808 @default.
• W2091462862 hasConcept C2777628954 @default.
• W2091462862 hasConcept C2777714996 @default.
• W2091462862 hasConcept C2780234812 @default.
• W2091462862 hasConcept C502942594 @default.
• W2091462862 hasConcept C526805850 @default.
• W2091462862 hasConcept C55493867 @default.
• W2091462862 hasConcept C71924100 @default.
• W2091462862 hasConcept C86803240 @default.
• W2091462862 hasConcept C98274493 @default.
• W2091462862 hasConceptScore W2091462862C112705442 @default.
• W2091462862 hasConceptScore W2091462862C114246631 @default.
• W2091462862 hasConceptScore W2091462862C121608353 @default.
• W2091462862 hasConceptScore W2091462862C126322002 @default.
• W2091462862 hasConceptScore W2091462862C149151106 @default.
• W2091462862 hasConceptScore W2091462862C150903083 @default.
• W2091462862 hasConceptScore W2091462862C181389837 @default.
• W2091462862 hasConceptScore W2091462862C185592680 @default.
• W2091462862 hasConceptScore W2091462862C207001950 @default.
• W2091462862 hasConceptScore W2091462862C2776256026 @default.
• W2091462862 hasConceptScore W2091462862C2777477808 @default.
• W2091462862 hasConceptScore W2091462862C2777628954 @default.
• W2091462862 hasConceptScore W2091462862C2777714996 @default.
• W2091462862 hasConceptScore W2091462862C2780234812 @default.
• W2091462862 hasConceptScore W2091462862C502942594 @default.
• W2091462862 hasConceptScore W2091462862C526805850 @default.
• W2091462862 hasConceptScore W2091462862C55493867 @default.
• W2091462862 hasConceptScore W2091462862C71924100 @default.
• W2091462862 hasConceptScore W2091462862C86803240 @default.
• W2091462862 hasConceptScore W2091462862C98274493 @default.
• W2091462862 hasLocation W20914628621 @default.
• W2091462862 hasOpenAccess W2091462862 @default.
• W2091462862 hasPrimaryLocation W20914628621 @default.
• W2091462862 hasRelatedWork W1455139017 @default.
• W2091462862 hasRelatedWork W1648151452 @default.
• W2091462862 hasRelatedWork W1983207529 @default.
• W2091462862 hasRelatedWork W1995391428 @default.
• W2091462862 hasRelatedWork W2003203356 @default.
• W2091462862 hasRelatedWork W2010974779 @default.
• W2091462862 hasRelatedWork W2020014049 @default.
• W2091462862 hasRelatedWork W2075737970 @default.
• W2091462862 hasRelatedWork W2077268629 @default.
• W2091462862 hasRelatedWork W2099364759 @default.
• W2091462862 hasRelatedWork W2132175919 @default.
• W2091462862 hasRelatedWork W2143404712 @default.
• W2091462862 hasRelatedWork W2147296852 @default.
• W2091462862 hasRelatedWork W2147774533 @default.
• W2091462862 hasRelatedWork W2154440819 @default.
• W2091462862 hasRelatedWork W2312799156 @default.
• W2091462862 hasRelatedWork W2318342353 @default.
• W2091462862 hasRelatedWork W2419060009 @default.
• W2091462862 hasRelatedWork W3029978173 @default.
• W2091462862 hasRelatedWork W2476196476 @default.
• W2091462862 isParatext "false" @default.
• W2091462862 isRetracted "false" @default.
• W2091462862 magId "2091462862" @default.
• W2091462862 workType "article" @default.